TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39324693

Group type: EXPERIMENTAL
Intervention: Daily cotrimoxazole prophylaxis plus mefloquine
Number of subjects: 4976

Group type: EXPERIMENTAL
Intervention: Daily cotrimoxazole prophylaxis plus dihydroartemisinin/piperaquine
Number of subjects: 4976
Study: 39324726

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study: 39324933

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) treatment
Number of subjects: 133
Study: 39325031

Group type: EXPERIMENTAL
Intervention: Maintained PEEP during awakening
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zero PEEP during awakening
Number of subjects: 60
Study: 39325087

Group type: EXPERIMENTAL
Intervention: Trauma-Focused CBT
Number of subjects: 183

Group type: COMPARATOR
Intervention: Stepped care CBT
Number of subjects: 183
Study: 39325123

Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for cervical cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catch-up vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling screening for HPV detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination
Number of subjects: 0
Study: 39325260

Group type: EXPERIMENTAL
Intervention: ddPCR assays for HPV16, 18, 33, 35, 56, and 59
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Posttreatment assessment of ctHPV-DNA levels
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Correlation analysis of ctHPV-DNA levels
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Detectable ctHPV-DNA posttreatment
Number of subjects: 119
Study: 39325310

Group type: EXPERIMENTAL
Intervention: ACP-led care
Number of subjects: 156

Group type: COMPARATOR
Intervention: Physician-led care
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 156
Study: 39325327

Group type: EXPERIMENTAL
Intervention: eTEP technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: TEP technique
Number of subjects: 60
Study: 39325391

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safety control
Number of subjects: 0
Study: 39325409

Group type: EXPERIMENTAL
Intervention: Brief online self-guided intervention for loneliness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer loneliness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control self-guided intervention (SSI)
Number of subjects: 0
Study: 39325429

Group type: EXPERIMENTAL
Intervention: Coping profile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Struggling profile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coping but concerned profile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General population of NSCLC patients
Number of subjects: 0
Study: 39325452

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) - weekly group or individual counseling
Number of subjects: 99

Group type: COMPARATOR
Intervention: Clinician-delivered CBT
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Digital CBT (CBT4CBT) plus brief weekly clinical monitoring
Number of subjects: 99
Study: 39325453

Group type: EXPERIMENTAL
Intervention: Tongxinluo (4 oral capsules, 3 times a day for 90 days)
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Control (placebo, 4 oral capsules, 3 times a day for 90 days)
Number of subjects: 2007
Study: 39325463

Group type: EXPERIMENTAL
Intervention: Oral everolimus 1.5-mg daily for 42 days after surgery
Number of subjects: 7
Study: 39325510

Group type: EXPERIMENTAL
Intervention: Ambulatory cognitive tests administered via smartphone app 4 times per day during a 14-day data collection period.
Number of subjects: 274

Group type: COMPARATOR
Intervention: In-person cognitive tests
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Ambulatory measures of physical activity, sleep, fatigue, pain, mood, and stress
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Ambulatory measures of cognitive functioning
Number of subjects: 274
Study: 39325643

Group type: EXPERIMENTAL
Intervention: Losartan 25-100 mg/day orally
Number of subjects: 341

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 341
Study: 39325778

Group type: EXPERIMENTAL
Intervention: Self-regulation intervention (culturally adapted Western expressive writing paradigm with emotional disclosure)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Self-cultivation intervention (originates from Asian cultural values without disclosing emotions)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control condition (writing about neutral topics)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Self-regulation intervention
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Self-cultivation intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 240
Study: 39325787

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Continued medical treatment of CRS
Number of subjects: 150
Study: 39325795

Group type: EXPERIMENTAL
Intervention: In-person auricular point acupressure (mAPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control (virtual APA; vAPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list usual care control (UC)
Number of subjects: 0
Study: 39325803

Group type: COMPARATOR
Intervention: Diagnostic algorithm developed using behavioral, neurophysiological, and MRI biomarkers from patients with FMD and healthy controls.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic value exploration of the diagnostic algorithm post-rehabilitation in a subgroup of patients with FMD.
Number of subjects: 0
Study: 39325828

Group type: EXPERIMENTAL
Intervention: Pfizer BNT162b2 vaccine
Number of subjects: 585
Study: 39326009

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg QD
Number of subjects: 787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study: 39326037

Group type: EXPERIMENTAL
Intervention: GPT-4 analysis of CT scans
Number of subjects: 208
Study: 39326042

Group type: EXPERIMENTAL
Intervention: 12-week aerobic-based interval cycling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-week balance and stretching intervention
Number of subjects: 0
Study: 39326051

Group type: EXPERIMENTAL
Intervention: Methylergonovine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carboprost
Number of subjects: 100
Study: 39326323

Group type: EXPERIMENTAL
Intervention: Primary or interval cytoreductive surgery (CRS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 8
Study: 39326356

Group type: EXPERIMENTAL
Intervention: Tidal volume ≥7 mL/kg PBW
Number of subjects: 600

Group type: COMPARATOR
Intervention: Tidal volume <7 mL/kg PBW
Number of subjects: 600
Study: 39326505

Group type: EXPERIMENTAL
Intervention: WBI+RNI
Number of subjects: 840

Group type: COMPARATOR
Intervention: WBI only
Number of subjects: 840
Study: 39326506

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 135
Study: 39326583

Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 143
Study: 39326675

Group type: EXPERIMENTAL
Intervention: Iron-corrected T1 mapping (cT1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Liver fat content (LFC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: cT1 reduction of ≥80 ms
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Liver fat reduction of ≥30%
Number of subjects: 150
Study: 39326699

Group type: EXPERIMENTAL
Intervention: Folate supplementation (FA)
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Cobalamin supplementation
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: MTHFR 677TT genotype with FA supplementation
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 831

Group type: COMPARATOR
Intervention: Suboptimal RBCF
Number of subjects: 831

Group type: COMPARATOR
Intervention: Suboptimal plasma cobalamin status
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Smoking and BMI
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Cobalamin status at labor
Number of subjects: 831
Study: 39326908

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Exercise therapy (12 weeks)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both treatments (APM and exercise therapy)
Number of subjects: 140
Study: 39326918

Group type: EXPERIMENTAL
Intervention: Selexipag (200-1600 µg twice daily titration until individual maximum tolerated dose) + standard of care
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo + standard of care
Number of subjects: 128
Study: 39326921

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39327049

Group type: COMPARATOR
Intervention: webinar (50 min virtual session standard of care)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: in-person education
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: video education
Number of subjects: 42
Study: 39327056

Group type: EXPERIMENTAL
Intervention: Higher post-filter ionised calcium target (0.35-0.45 mmol/L)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Lower post-filter ionised calcium target (0.25-0.35 mmol/L)
Number of subjects: 412
Study: 39327172

Group type: EXPERIMENTAL
Intervention: Mobilisation with movement (MWM) plus exercise
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham mobilisation with movement plus exercise
Number of subjects: 70
Study: 39327269

Group type: EXPERIMENTAL
Intervention: IRBD-SSS-PT (patient version)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: IRBD-SSS-BP (bedpartner version)
Number of subjects: 188
Study: 39327291

Group type: EXPERIMENTAL
Intervention: Waiting time exceeding 6 months
Number of subjects: 232
Study: 39327294

Group type: EXPERIMENTAL
Intervention: Polypectomy repeated twice during the withdrawal phase after initial insertion of the colonoscope (study group).
Number of subjects: 406

Group type: COMPARATOR
Intervention: Standard colonoscopy method with observation and polypectomy once (control group).
Number of subjects: 406
Study: 39327433

Group type: EXPERIMENTAL
Intervention: Surufatinib (200 mg, qd, po) plus toripalimab (240 mg, d1, ivdrip) combined with etoposide (100 mg/m², d1-d3, iv, drip) and cisplatin (25 mg/m², d1-d3, ivdrip)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Surufatinib, toripalimab, etoposide plus cisplatin
Number of subjects: 38
Study: 39327563

Group type: EXPERIMENTAL
Intervention: One session of low-level laser therapy (LLLT) per week for 4 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Two sessions of low-level laser therapy (LLLT) per week for 4 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Three sessions of low-level laser therapy (LLLT) per week for 4 weeks
Number of subjects: 90
Study: 39327613

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine (SP + AQ)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Artesunate (AS)
Number of subjects: 900
Study: 39327830

Group type: EXPERIMENTAL
Intervention: Structured contraceptive counseling
Number of subjects: 770

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 770
Study: 39327857

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF) 25 mg/day
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg/day
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Switch from TDF to TAF at year 2 (TDF2y → TAF6y)
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Switch from TDF to TAF at year 3 (TDF3y → TAF5y)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Long-term TAF treatment
Number of subjects: 1298
Study: 39328083

Group type: EXPERIMENTAL
Intervention: SR group (telerehabilitation using the SR device for 20 hours over 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham device group (training with pictorial handouts and a sham device for 20 hours over 4 weeks)
Number of subjects: 40
Study: 39328096

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 or 30 mg (± 4-week 200-mg loading dose) for 24 weeks
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 or 30 mg for 24 weeks
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 718
Study: 39328202

Group type: EXPERIMENTAL
Intervention: PR-ERAS (prehabilitation exercises with standard ERAS)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: PR-ERAS
Number of subjects: 95

Group type: COMPARATOR
Intervention: S-ERAS
Number of subjects: 95
Study: 39328312

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow derived mesenchymal stromal cells (MSC)
Number of subjects: 7
Study: 39328391

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment expectation measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clusters for individualized interventions
Number of subjects: 0
Study: 39328464

Group type: EXPERIMENTAL
Intervention: Protein-supplemented very-low-calorie diet (PSVLCD)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (food-based calorie-restricted diet)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: PSVLCD
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 39328508

Group type: EXPERIMENTAL
Intervention: 60-h fast followed by a 48-h refeeding period
Number of subjects: 0
Study: 39328832

Group type: EXPERIMENTAL
Intervention: Video-guided active breaks through the 'Active Classes' web platform, lasting 5-10 minutes, moderate to vigorous intensity, twice a day, for 12 weeks.
Number of subjects: 823

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Video-guided active breaks with curricular content.
Number of subjects: 823
Study: 39328897

Group type: EXPERIMENTAL
Intervention: Internet-based lifestyle intervention via a secure web application for one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-based lifestyle intervention
Number of subjects: 0
Study: 39328900

Group type: EXPERIMENTAL
Intervention: Dexamethasone intracanalicular insert (DEX)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo insert (PBO)
Number of subjects: 96
Study: 39328960

Group type: EXPERIMENTAL
Intervention: Cannabis cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 39328985

Group type: EXPERIMENTAL
Intervention: SPMS
Number of subjects: 149
Study: 39329073

Group type: EXPERIMENTAL
Intervention: Conventional vascular access (predicted by AVAS)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Unconventional vascular access (not predicted by AVAS)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: AVAS classification
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Clinician prediction of VA
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: AVAS classes
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: AVAS assessment
Number of subjects: 1034
Study: 39329200

Group type: EXPERIMENTAL
Intervention: Muvalaplin
Number of subjects: 0
Study: 39329205

Group type: EXPERIMENTAL
Intervention: Broad-Minded Affective Coping (BMAC)
Number of subjects: 16
Study: 39329240

Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Number of subjects: 1372
Study: 39329272

Group type: EXPERIMENTAL
Intervention: DNG/EE treatment
Number of subjects: 80
Study: 39329336

Group type: EXPERIMENTAL
Intervention: Total follicle count
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Larger follicles (≥5mm)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Circulating E1 and E2 levels
Number of subjects: 302
Study: 39330494

Group type: EXPERIMENTAL
Intervention: Improvement of glycemic control through medical intervention (insulin introduction, changes in multi-injection therapy, pump therapy introduction, therapeutic education)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Improvement of glycemic control
Number of subjects: 98
Study: 39330966

Group type: EXPERIMENTAL
Intervention: Full dose of PCV13
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 40% dose of PCV13
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20% dose of PCV13
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Full dose of PCV10
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 40% dose of PCV10
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20% dose of PCV10
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Full dose of PCV10 (three primary doses without a booster)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vaccine-serotype carriage
Number of subjects: 7
Study: 39331127

Group type: EXPERIMENTAL
Intervention: TachoSil® as a ventricular sealant
Number of subjects: 39
Study: 39331131

Group type: EXPERIMENTAL
Intervention: Anatomic treatment
Number of subjects: 209

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 209
Study: 39331218

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: topical therapy or methotrexate
Number of subjects: 80

Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 80
Study: 39331462

Group type: EXPERIMENTAL
Intervention: Routine use of a 3D mapping system during right-sided ablation
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Zero fluoroscopy exposure
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Minimal fluoroscopic exposure techniques
Number of subjects: 680
Study: 39331470

Group type: EXPERIMENTAL
Intervention: Antisense Oligonucleotides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39331638

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg and 100 mg
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Filgotinib and Adalimumab
Number of subjects: 425
Study: 39331724

Group type: EXPERIMENTAL
Intervention: Daratumumab and lenalidomide (D-R) maintenance therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard-of-care lenalidomide (R) alone
Number of subjects: 200
Study: 39331837

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of EVR with decreased doses of calcineurin inhibitors (tacrolimus, cyclosporine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVR TDM for pancreatic and islet transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacodynamic monitoring of EVR
Number of subjects: 0
Study: 39332270

Group type: EXPERIMENTAL
Intervention: Moderate OSA group (AHI 15-30)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nil-mild OSA group (AHI <15)
Number of subjects: 51
Study: 39332395

Group type: EXPERIMENTAL
Intervention: Finerenone (titrated to either 20 mg or 40 mg)
Number of subjects: 6001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study: 39332418

Group type: EXPERIMENTAL
Intervention: mRNA-1273.222 (50 μg dose)
Number of subjects: 379
Study: 39332633

Group type: EXPERIMENTAL
Intervention: Vunakizumab 240 mg
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study: 39332892

Group type: EXPERIMENTAL
Intervention: Severe ROP (n=3130)
Number of subjects: 19863

Group type: EXPERIMENTAL
Intervention: Cerebral injury (n=2836)
Number of subjects: 19863

Group type: EXPERIMENTAL
Intervention: Severe ROP and Cerebral injury (n=1438)
Number of subjects: 19863
Study: 39332900

Group type: EXPERIMENTAL
Intervention: Medical management (MM) with spontaneous recanalization (SR)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Medical management (MM) without spontaneous recanalization (SR)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Endovascular therapy (EVT) recanalization
Number of subjects: 184
Study: 39333103

Group type: EXPERIMENTAL
Intervention: CAR-T cells derived from central memory cells of healthy donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Over-expression of KLF7 in CAR-T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histone mark analyses
Number of subjects: 0
Study: 39333315

Group type: EXPERIMENTAL
Intervention: autologous anti-CD123 CAR T cells
Number of subjects: 12
Study: 39333450

Group type: EXPERIMENTAL
Intervention: High-risk LARC with NAT (HiN)
Number of subjects: 381

Group type: COMPARATOR
Intervention: High-risk LARC with primary surgery (HiS)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Low-risk LARC with NAT (LoN)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Low-risk LARC with primary surgery (LoS)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Salvage surgery
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Single-site recurrence
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment after primary surgery
Number of subjects: 381
Study: 39333875

Group type: EXPERIMENTAL
Intervention: Rimegepant
Number of subjects: 133
Study: 39333902

Group type: EXPERIMENTAL
Intervention: Novel semi-facial respirator with chitosan nanoparticles
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conventional N95 respirator
Number of subjects: 230